NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Cisplatin, Irinotecan, and Bevacizumab, in Treating Patients With Small Cell Lung Cancer

Phase 2

Completed

Conditions: Extensive Stage Small Cell Lung Cancer

Interventions: Drug: cisplatin
Drug: irinotecan hydrochloride
Biological: bevacizumab
Other: laboratory biomarker analysis

First Posted Date: 2005-07-11

Last Posted Date: 2014-06-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 72

Registration Number: NCT00118235

Locations: 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States
🇺🇸
Rhode Island Hospital, Providence, Rhode Island, United States

17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Anaplastic Large Cell Lymphoma
Recurrent Adult Hodgkin Lymphoma
Recurrent Mantle Cell Lymphoma

Interventions: Drug: tanespimycin

First Posted Date: 2005-07-11

Last Posted Date: 2014-05-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 22

Registration Number: NCT00117988

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer

Phase 2

Completed

Conditions: Recurrent Thyroid Cancer
Stage IV Follicular Thyroid Cancer
Stage IV Papillary Thyroid Cancer
Thyroid Gland Medullary Carcinoma

Interventions: Drug: tanespimycin

First Posted Date: 2005-07-11

Last Posted Date: 2017-02-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 41

Registration Number: NCT00118248

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy

Phase 2

Completed

Conditions: Adenocarcinoma of the Prostate
Stage IV Prostate Cancer
Recurrent Prostate Cancer

Interventions: Drug: tanespimycin
Other: laboratory biomarker analysis

First Posted Date: 2005-07-11

Last Posted Date: 2017-04-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 17

Registration Number: NCT00118092

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function

Phase 1

Completed

Conditions: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Nodal Marginal Zone B-cell Lymphoma
Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
Recurrent Adult Grade III Lymphomatoid Granulomatosis
Recurrent Grade 3 Follicular Lymphoma
Splenic Marginal Zone Lymphoma
Stage III Marginal Zone Lymphoma
Recurrent Adult Burkitt Lymphoma
Recurrent Mantle Cell Lymphoma
Stage III Adult Immunoblastic Large Cell Lymphoma

Interventions: Drug: sorafenib tosylate
Other: pharmacological study

First Posted Date: 2005-07-11

Last Posted Date: 2013-01-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 150

Registration Number: NCT00118170

Locations: 🇺🇸
Cancer and Leukemia Group B (CALGB) Research Base, Chicago, Illinois, United States

Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Adenocarcinoma of the Lung
Adenosquamous Cell Lung Cancer
Large Cell Lung Cancer
Malignant Pleural Effusion
Recurrent Non-small Cell Lung Cancer
Squamous Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer

Interventions: Drug: docetaxel
Biological: cetuximab
Drug: bortezomib

First Posted Date: 2005-07-11

Last Posted Date: 2013-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 62

Registration Number: NCT00118183

Locations: 🇺🇸
Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States

Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer

Phase 2

Completed

Conditions: Stage II Bladder Cancer AJCC v6 and v7
Recurrent Bladder Carcinoma
Stage III Bladder Cancer AJCC v6 and v7
Stage I Bladder Cancer AJCC v6 and v7

Interventions: Other: Laboratory Biomarker Analysis
Drug: Genistein
Other: Placebo Administration
Other: Pharmacological Study
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2005-07-11

Last Posted Date: 2021-06-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT00118040

Locations: 🇺🇸
University of Wisconsin Chemoprevention Consortium, Madison, Wisconsin, United States
🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
🇺🇸
Saint Vincent Hospital Cancer Center Green Bay, Green Bay, Wisconsin, United States

and more 7 locations

Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps

Phase 3

Completed

Conditions: Precancerous Condition

Interventions: Other: placebo
Drug: eflornithine
Other: laboratory biomarker analysis
Drug: sulindac

First Posted Date: 2005-07-11

Last Posted Date: 2015-01-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 375

Registration Number: NCT00118365

Locations: 🇺🇸
University of California Medical Center At Irvine-Orange Campus, Orange, California, United States

Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer

Phase 2

Completed

Conditions: Bronchoalveolar Cell Lung Cancer
Non-small Cell Lung Cancer
Adenocarcinoma of the Lung
Recurrent Non-small Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer

Interventions: Drug: bortezomib

First Posted Date: 2005-07-11

Last Posted Date: 2014-08-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 42

Registration Number: NCT00118144

Locations: 🇺🇸
City of Hope, Duarte, California, United States

Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen

Phase 2

Completed

Conditions: Male Breast Carcinoma
Estrogen Receptor Positive
Recurrent Breast Carcinoma
Stage IIIB Breast Cancer
Stage IIIC Breast Cancer
Progesterone Receptor Positive
Stage IV Breast Cancer

Interventions: Other: Laboratory Biomarker Analysis
Drug: Lapatinib Ditosylate
Drug: Tamoxifen Citrate

First Posted Date: 2005-07-11

Last Posted Date: 2017-12-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 19

Registration Number: NCT00118157

Locations: 🇺🇸
Harper University Hospital - DMC, Detroit, Michigan, United States
🇺🇸
Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States

AI-Powered Research

Premium Access

NATIONAL INSTITUTES OF HEALTH

Cisplatin, Irinotecan, and Bevacizumab, in Treating Patients With Small Cell Lung Cancer

17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma

Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer

17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy

Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function

Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer

Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps

Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer

Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen